Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT908 | Individual Protein | Ribonuclease pancreatic | Bos taurus | Ki | = | 82000 | nM | 19173562 |
NPT909 | Individual Protein | Seminal ribonuclease | Bos taurus | Ki | = | 63200 | nM | 19643512 |
NPT908 | Individual Protein | Ribonuclease pancreatic | Bos taurus | Ki | = | 78500 | nM | 19643512 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC36985 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
1.0 | High Similarity | NPC17892 |
0.9885 | High Similarity | NPC283698 |
0.9885 | High Similarity | NPC73765 |
0.9651 | High Similarity | NPC324390 |
0.954 | High Similarity | NPC322594 |
0.954 | High Similarity | NPC320249 |
0.9186 | High Similarity | NPC43246 |
0.9186 | High Similarity | NPC89051 |
0.9011 | High Similarity | NPC317639 |
0.8866 | High Similarity | NPC329277 |
0.8837 | High Similarity | NPC106780 |
0.8687 | High Similarity | NPC149843 |
0.8687 | High Similarity | NPC155087 |
0.8681 | High Similarity | NPC327344 |
0.8495 | Intermediate Similarity | NPC324516 |
0.8495 | Intermediate Similarity | NPC318166 |
0.8462 | Intermediate Similarity | NPC315063 |
0.8242 | Intermediate Similarity | NPC210456 |
0.8242 | Intermediate Similarity | NPC163352 |
0.8211 | Intermediate Similarity | NPC226769 |
0.8211 | Intermediate Similarity | NPC280946 |
0.8211 | Intermediate Similarity | NPC6166 |
0.8125 | Intermediate Similarity | NPC120887 |
0.8041 | Intermediate Similarity | NPC328779 |
0.7938 | Intermediate Similarity | NPC90240 |
0.7912 | Intermediate Similarity | NPC71339 |
0.7912 | Intermediate Similarity | NPC112842 |
0.7879 | Intermediate Similarity | NPC328914 |
0.7826 | Intermediate Similarity | NPC325723 |
0.7732 | Intermediate Similarity | NPC329384 |
0.7727 | Intermediate Similarity | NPC329077 |
0.7544 | Intermediate Similarity | NPC284651 |
0.75 | Intermediate Similarity | NPC171116 |
0.7474 | Intermediate Similarity | NPC190334 |
0.7474 | Intermediate Similarity | NPC62927 |
0.7158 | Intermediate Similarity | NPC229249 |
0.7065 | Intermediate Similarity | NPC325902 |
0.67 | Remote Similarity | NPC328806 |
0.6612 | Remote Similarity | NPC315058 |
0.6598 | Remote Similarity | NPC319753 |
0.6452 | Remote Similarity | NPC315806 |
0.6452 | Remote Similarity | NPC313962 |
0.6311 | Remote Similarity | NPC109188 |
0.6293 | Remote Similarity | NPC478024 |
0.6179 | Remote Similarity | NPC325750 |
0.6124 | Remote Similarity | NPC318142 |
0.5738 | Remote Similarity | NPC313813 |
0.5657 | Remote Similarity | NPC470782 |
0.5612 | Remote Similarity | NPC126186 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC36985 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.9885 | High Similarity | NPD9639 | Clinical (unspecified phase) |
0.9186 | High Similarity | NPD9581 | Clinical (unspecified phase) |
0.9186 | High Similarity | NPD9580 | Clinical (unspecified phase) |
0.8866 | High Similarity | NPD3129 | Phase 3 |
0.8763 | High Similarity | NPD3128 | Phase 3 |
0.8636 | High Similarity | NPD9557 | Clinical (unspecified phase) |
0.8191 | Intermediate Similarity | NPD1686 | Approved |
0.8182 | Intermediate Similarity | NPD9556 | Approved |
0.8172 | Intermediate Similarity | NPD9565 | Discontinued |
0.8144 | Intermediate Similarity | NPD5789 | Clinical (unspecified phase) |
0.8113 | Intermediate Similarity | NPD3139 | Phase 3 |
0.809 | Intermediate Similarity | NPD9560 | Approved |
0.809 | Intermediate Similarity | NPD9561 | Approved |
0.8065 | Intermediate Similarity | NPD755 | Phase 3 |
0.8019 | Intermediate Similarity | NPD3138 | Phase 3 |
0.8 | Intermediate Similarity | NPD9546 | Phase 2 |
0.7978 | Intermediate Similarity | NPD9558 | Phase 3 |
0.7912 | Intermediate Similarity | NPD9533 | Phase 2 |
0.7912 | Intermediate Similarity | NPD280 | Approved |
0.7879 | Intermediate Similarity | NPD1455 | Phase 3 |
0.7879 | Intermediate Similarity | NPD1454 | Phase 3 |
0.7857 | Intermediate Similarity | NPD502 | Approved |
0.7849 | Intermediate Similarity | NPD241 | Discontinued |
0.7742 | Intermediate Similarity | NPD9562 | Discovery |
0.7742 | Intermediate Similarity | NPD170 | Approved |
0.7742 | Intermediate Similarity | NPD240 | Phase 3 |
0.7664 | Intermediate Similarity | NPD7914 | Suspended |
0.7609 | Intermediate Similarity | NPD9529 | Phase 1 |
0.7609 | Intermediate Similarity | NPD9559 | Phase 1 |
0.7551 | Intermediate Similarity | NPD501 | Phase 1 |
0.7527 | Intermediate Similarity | NPD239 | Phase 2 |
0.7527 | Intermediate Similarity | NPD238 | Clinical (unspecified phase) |
0.75 | Intermediate Similarity | NPD841 | Approved |
0.75 | Intermediate Similarity | NPD6946 | Approved |
0.7474 | Intermediate Similarity | NPD9602 | Phase 3 |
0.7474 | Intermediate Similarity | NPD9603 | Phase 3 |
0.7474 | Intermediate Similarity | NPD9604 | Approved |
0.74 | Intermediate Similarity | NPD762 | Discontinued |
0.7347 | Intermediate Similarity | NPD251 | Approved |
0.7308 | Intermediate Similarity | NPD1061 | Clinical (unspecified phase) |
0.7172 | Intermediate Similarity | NPD6943 | Clinical (unspecified phase) |
0.7172 | Intermediate Similarity | NPD9585 | Discontinued |
0.7158 | Intermediate Similarity | NPD9601 | Approved |
0.7113 | Intermediate Similarity | NPD1760 | Approved |
0.7019 | Intermediate Similarity | NPD223 | Clinical (unspecified phase) |
0.7018 | Intermediate Similarity | NPD7756 | Clinical (unspecified phase) |
0.6944 | Remote Similarity | NPD1385 | Discontinued |
0.6893 | Remote Similarity | NPD514 | Clinical (unspecified phase) |
0.6887 | Remote Similarity | NPD7651 | Approved |
0.6869 | Remote Similarity | NPD9554 | Approved |
0.6869 | Remote Similarity | NPD9553 | Approved |
0.6869 | Remote Similarity | NPD301 | Discontinued |
0.6842 | Remote Similarity | NPD9600 | Approved |
0.6765 | Remote Similarity | NPD279 | Clinical (unspecified phase) |
0.6733 | Remote Similarity | NPD267 | Discontinued |
0.6719 | Remote Similarity | NPD7761 | Suspended |
0.6701 | Remote Similarity | NPD9572 | Clinical (unspecified phase) |
0.6638 | Remote Similarity | NPD7992 | Clinical (unspecified phase) |
0.6604 | Remote Similarity | NPD192 | Phase 2 |
0.6598 | Remote Similarity | NPD9573 | Phase 2 |
0.6569 | Remote Similarity | NPD500 | Discontinued |
0.6538 | Remote Similarity | NPD215 | Discontinued |
0.6452 | Remote Similarity | NPD9653 | Clinical (unspecified phase) |
0.64 | Remote Similarity | NPD9555 | Phase 2 |
0.6392 | Remote Similarity | NPD9429 | Discontinued |
0.6364 | Remote Similarity | NPD9503 | Approved |
0.6364 | Remote Similarity | NPD9504 | Approved |
0.6321 | Remote Similarity | NPD6948 | Phase 3 |
0.6316 | Remote Similarity | NPD9407 | Approved |
0.6311 | Remote Similarity | NPD1331 | Approved |
0.6306 | Remote Similarity | NPD2633 | Phase 1 |
0.6306 | Remote Similarity | NPD4743 | Phase 2 |
0.6289 | Remote Similarity | NPD9427 | Approved |
0.6261 | Remote Similarity | NPD1805 | Phase 2 |
0.6261 | Remote Similarity | NPD1804 | Phase 2 |
0.6195 | Remote Similarity | NPD1428 | Phase 2 |
0.6174 | Remote Similarity | NPD284 | Phase 1 |
0.61 | Remote Similarity | NPD2691 | Clinical (unspecified phase) |
0.6087 | Remote Similarity | NPD6693 | Phase 3 |
0.6 | Remote Similarity | NPD3121 | Phase 2 |
0.6 | Remote Similarity | NPD9405 | Approved |
0.598 | Remote Similarity | NPD205 | Approved |
0.596 | Remote Similarity | NPD9403 | Discontinued |
0.595 | Remote Similarity | NPD6935 | Phase 3 |
0.595 | Remote Similarity | NPD6936 | Clinical (unspecified phase) |
0.5946 | Remote Similarity | NPD765 | Discontinued |
0.5888 | Remote Similarity | NPD285 | Discontinued |
0.5789 | Remote Similarity | NPD244 | Clinical (unspecified phase) |
0.578 | Remote Similarity | NPD1706 | Clinical (unspecified phase) |
0.5607 | Remote Similarity | NPD723 | Phase 2 |
PubChem CID   | 101543 |
ChEMBL   | CHEMBL460741 |
ZINC   |
Molecular Weight:   | 324.04 |
ALogP:   | -2.4823 |
MLogP:   | 1.13 |
XLogP:   | -3.869 |
# Rotatable Bonds:   | 9 |
Polar Surface Area:   | 179.16 |
# H-Bond Aceptor:   | 11 |
# H-Bond Donor:   | 5 |
# Rings:   | 2 |
# Heavy Atoms:   | 21 |